Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

GlobeNewswire April 13, 2023

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

GlobeNewswire March 30, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

GlobeNewswire March 14, 2023

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire March 2, 2023

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

GlobeNewswire March 1, 2023

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire February 28, 2023

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

GlobeNewswire February 21, 2023

Allogene Therapeutics Presents Data on Dagger(TM), a Next Generation AlloCAR T(TM) Platform Technology

GlobeNewswire February 1, 2023

Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm

Newsfile January 25, 2023

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T(TM) Target for Small Cell Lung Cancer

GlobeNewswire January 25, 2023

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

GlobeNewswire January 24, 2023

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire January 17, 2023

Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm

PR Newswire January 5, 2023

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

GlobeNewswire January 3, 2023

Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm

Newsfile December 4, 2022

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T(TM) Platform

GlobeNewswire November 29, 2022

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T(TM) Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire November 10, 2022

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

GlobeNewswire November 9, 2022

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

GlobeNewswire November 3, 2022